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Abstract:  Infections caused by Achromobacter xylosoxidans cause significant morbidity and mortality in 
debilitated individuals. Eradication of these infections requires prolonged therapy with antimicrobial agents 
and removal of any infected central venous catheter. The outcome is usually poor in patients with high risk 
malignancy, septic complications, and/or multi-organ dysfunction. 
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Introduction 
Achromobacter xylosoxidans ( A. xylosoxidans) 
is a Gram-negative bacillus which can cause 
severe infection with a high mortality rate, 
particularly in immunocompromised individuals 
despite its low intrinsic pathogenicity [1-6].
 Several 
clinical syndromes have been described including 
primary bacteremia, meningitis, and pneumonia [3-
8]. The lack of standard therapy and the resistance 
to several antibiotics render the management of 
infections caused by this organism difficult [4, 6, 9-
13]. 
This report describes a young patient with acute 
lymphoblastic leukemia (ALL) who suffered 
several bacterial infections during and after 
induction chemotherapy given at Riyadh Armed 
Forces Hospital. Afterward, while receiving 
treatment in the general intensive care unit (ICU), 
the patient developed A. xylosoxidans  
bacteremia,  complicated by septic shock and 
multiorgan  failure. 
 
Case Report 
A nineteen year old Saudi male with 
Philadelphia positive ALL presented with fever. 
General and systemic examinations were 
unremarkable with no evidence of palpable 
lymphadenopathy or abdominal organomegaly. 
Chemistries on admission revealed:  anaemia, 
thrombocytopenia and hypercalcemia. However, 
his white cell count was normal. After correcting 
the hypercalcemia with intravenous fluids and 
clodronate, the patient was started on UK XII ALL 
induction chemotherapy composed of 
prednisolone, vincristine, idarubicin and L-
asparaginase in addition to intrathecal 
methotrexate. Ten days later, the patient 
experienced fever and diarrhea. Blood cultures 
grew  E.coli and Klebsiella pneumoniae. 
Intravenous ceftazidime and amikacin were started 
according to  susceptibility  results. The patient 
responded well to treatment and  remained 
clinically stable for about ten days. 
Three weeks after starting chemotherapy, the 
patient developed a small painful nodule over the 
left thigh. Cultures from the left groin  grew a 
highly resistant Pseudomonas aeruginosa 
sensitive only to ciprofloxacin and imipenem. 
Methicillin resistant Staphylococcus aureus 
(MRSA) was cultured from a nasal swab and 
E.coli grew from a urine sample. Recent cultures 
were reviewed, and it was decided to change 
ceftazidime and amikacin to imipenem, 
ciprofloxacin, and vancomycin for additional gram 
positive bacterial coverage, since the patient was 
continuously febrile. The central venous catheter 
was removed, the induction course of 
chemotherapy was placed on hold, and 
granulocyte-colony stimulating factor (G-CSF) was 
initiated. Despite measures taken, the patient 
remained pyrexial and the thigh nodule developed 
into cellulitis with a fluid collection. Surgical 
incision and drainage was required, but the patient 
continued to deteriorate with the cellulitis 
extending toward the perineum. The patient 
remained febrile, and became hypotensive. He 
was transferred to the intensive care unit.  
The patient had a slow and complex recovery.  
Eight days after the first septic episode, he 
became hemodynamically unstable and required 
ventilatory and inotropic support. Central and 
peripheral blood cultures were repeated which 
grew a gram negative bacillus identified as A. 
xylosoxidans. The organism was classified as an 
oxidizer in the glucose oxidative fermentation 
medium. It oxidized xylose better than glucose. It 
was oxidase and nitrate positive and had a 
negative reaction for urea, mannitol, sucrose, and 
maltose.  The antimicrobial susceptibility testing 
was performed with disc diffusion method 
according to the CLSI (Clinical and Laboratory 
Standards Institute). The cultured organism was 
found to be sensitive to colistin, imipenem, 
ceftazidime and piperacillin/tazobactam. Despite 
the addition of intravenous colistin to the previous 
antibiotic coverage and despite the removal of the 
central venous catheter, the patient deteriorated 
further,  had  cardiac arrest, and died. 
 
Discussion 
A. xylosoxidans is an aerobic, non-fermenting, 
Gram-negative rod initially characterized by 
Holmes and further studied and named by 
Yabuuchi and Ohyama (1971) after isolation of the 
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organism from seven patients with chronic otitis 
media [1,14]. It is often encountered in aqueous 
environments but rarely recognized as a human 
pathogen. Despite its low intrinsic pathogenicity, it 
can cause serious infections in humans, especially 
immunocompromised hosts [8, 11, 12]. A. 
xylosoxidans  has been reported in patients with 
cancer, neutropenia, bone marrow or liver 
transplant, diabetes mellitus, renal failure, cystic 
fibrosis, HIV infection, IgM deficiency, neonates, 
and healthy individuals [2-4, 5-8,10,11,13,15-17]. 
The clinical manifestation of infection caused by A. 
xylosoxidans is variable and includes primary 
bacteremia, pneumonia, meningitis, endocarditis, 
cholecystitis, peritonitis, pyelonephritis, 
osteomyelitis, lymphadenitis and keratitis [3-6, 8, 
14, and 18]. 
Treatment of infections caused by this organism 
is usually difficult as multidrug resistance is 
commonly encountered and as the optimal therapy 
isnotyet determined [5, 10-12, 16]. However, 
previous reports have found that empirical 
antibiotic therapy with piperacillin-tazobactam or a 
carbapenem would be a reasonable choice until 
results of susceptibility tests are available. A. 
xylosoxidans  is characteristically susceptible to 
trimethoprim/sulphamethoxazole, colistin, 
antipseudomonal penicillins, and carbapenems. It 
is usually resistant to aminoglycosides, ampicillin, 
aztreonam, quinolones and most of the 
cephalosporins [1, 4, 6, 9-13]. Eradication of these 
infections requires prolonged therapy with drug 
combinations as well as the removal of  infected 
central venous catheters [2, 12, 15, and 18]. Poor 
prognosis and high mortality rates are expected in 
neonates, elderly individuals, patients with   
malignancies, neutropenia, sepsis syndrome, 
multi-organ failure, those on mechanical 
ventilation, and patients having meningitis, 
endocarditis and pneumonia [3-7, 9].
  Hoewever, 
catheter-related infections are associated with low 
mortality rates [3, 4]. Infection outbreaks should be 
recognized and appropriate infection control 
measures taken [12]. 
 
Conclusion 
 A. xylosoxidans is a Gram-negative oxidative 
organism which causes infections in patients with 
certain underlying illnesses. It is a rare but an 
important cause of bacteremia in 
immunocompromised individuals. The strains are 
often resistant to multiple antimicrobials. Empirical 
antibiotic therapy with piperacillin- tazobactam or a 
carbapenem is a reasonable choice until the 
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